Eli Lilly (LLY) Q3 2024 Earnings Call Transcript
Operator instructions] I would now like to turn the conference over to your host, Joe Fletcher, senior vice president of investor relations. Please go ahead.Joe Fletcher -- Senior Vice President, Investor Relations Thank you,
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook observed through 1H24. Read more here.
Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations
Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug space.
Eli Lilly Stock Tumbles as Q3 Sales, Profits Fall Well Short of Estimates
Eli Lilly shares sank 10% Wednesday morning after its third-quarter results came in well below what analysts were expecting.
Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
LLY had $11.4 billion in revenue for the quarter (up 20% versus Q3 figures from last year), with a net income of $970 million after expenses. Let's parse this earnings statement for details.
Eli Lilly Shares Tumble After Disappointing Q3 Earnings Report
Eli Lilly shares fell up to 10% after Q3 earnings missed Wall Street expectations, reporting $11.4 billion in revenue and lowering profit guidance.
Eli Lilly And Co. Q3 Earnings Summary
Below are the earnings highlights for Eli Lilly And Co. (LLY): Earnings: $970.3 million in Q3 vs. -$57.4 million in the same period
Eli Lilly (LLY) Lags Q3 Earnings and Revenue Estimates
Eli Lilly (LLY) came out with quarterly earnings of $1.18 per share, missing the Zacks Consensus Estimate of $1.52 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
Eli Lilly drops, sending Novo lower after Q3 miss
Eli Lilly (LLY) stock drops hurting its rival Novo Nordisk (NVO) after the U.S. drugmaker missed forecasts with Q3 financials and weight loss drugs. Read more here.
Eli Lilly core thesis ‘remains intact’ despite Q3 miss, says JPMorgan
After Eli Lilly (LLY) reported Q3 results that are below the Street view on sales and EPS due to Zepbound and Mounjaro wholesaler destocking
Eli Lilly Q3 earnings expected to beat Wall Street expectations
Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug space.
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains (CORRECTED)
Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing ...
Why Eli Lilly Stock Is Sinking Today
Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...
Eli Lilly Stock Dives Toward Worst Day Since 2000 On Disappointing Earnings, Zepbound Sales
Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking ...
Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks
Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...